Mandate

Vinge has advised Egetis Therapeutics in connection with directed share issuances

October 03, 2024

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with directed share issuances whereby Egetis Therapeutics receives gross proceeds of SEK 300 million.

The share issuances were directed to a number of international and Swedish institutional investors on the basis of an accelerated bookbuilding process. One of the issuances is subject to approval by an extraordinary general meeting as well as approval and publication of a prospectus.

Vinge’s team consisted of Dain Hård Nevonen, Lorin Arabi and Karin Karsten.

Related

Vinge advises Setra Trävaror in conjunction with the sale of Malå Såg to HS Timber

The Austrian company HS Timber Group has entered into an agreement to acquire 100 per cent of the shares in the Swedish wood processing company Malå Såg AB from Setra Trävaror AB, a subsidiary of Setra Group AB. The transaction remains subject to approval from the relevant public authorities.
October 29, 2025

Vinge has advised Advania on the acquisition of Visuell Teknik

Advania has acquired Visuell Teknik, a Swedish provider of audiovisual and meeting technology solutions.
October 28, 2025

Vinge has advised Acrinova in connection with voluntary share redemption offering

Vinge has advised Acrinova AB (publ) in connection with its voluntary share redemption offering. The offer comprised approximately one-third of the shares in Acrinova, and the acceptance rate reached approximately 97.34 percent, representing a redemption value of approximately SEK 367.4 million.
October 27, 2025